Biologics/Update·FDA Vaccines, Blood & Biologics

Regulatory Education for Industry (REdI) Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products - 05/19/2026

MediumPublished May 4, 2026· AI-analyzed May 4, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

The FDA announced the Regulatory Education for Industry (REdI) Annual Conference 2026, scheduled for May 19, 2026. The event features experts from the CDER, CBER, and CDRH centers focusing on innovative regulatory strategies for medical products.

Who it affects

This event affects regulatory affairs, clinical, and quality professionals within the drug, medical device, and biologics industries who are seeking direct technical guidance from agency experts.

Why it matters

Participation in REdI conferences typically provide industry with insights into the agency's current thinking on submission pathways and compliance standards. This suggests a focus on non-traditional or modernized regulatory approaches that could impact how companies structure their development programs and interactions with medical product centers.

Practical takeaway

Regulatory leads should monitor for session agendas to identify specific technical tracks relevant to their product portfolios. Teams should consider this an opportunity for direct engagement with agency experts to clarify expectations on innovative submission strategies.

FDA source material

Learn directly from the FDA’s regulatory experts in medical product centers: drugs, devices, and biologics.

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.